Does breast cancer drug trastuzumab cause dry eye?

NCT ID NCT07666724

Completed Knowledge-focused Sponsor: Semmelweis University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from Semmelweis University looked at whether the breast cancer drug trastuzumab (Herceptin) causes dry eye or other eye surface problems. 35 adults with HER2-positive breast cancer took the drug as prescribed and visited the clinic every 3 months for eye exams. Researchers measured tear film stability and eye discomfort to see if the drug affects eye health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab (Herceptin)
What this could lead to: If successful, this could help doctors monitor and manage dry eye side effects in breast cancer patients receiving trastuzumab.
What could go wrong: This was a small, completed study with only 35 participants, so results may not apply to all patients. It only looked at eye symptoms, not overall treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM, EXERCISE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM, EXERCISE

Contacts and locations

Locations

Semmelweis University Ophthalmology Department

Budapest, 1085, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.